



CEO: Edward Fotsch, MD President: Richard C. Altus Chief Medical Officer: Steven Merahn, MD Chief Technology Officer: David Cheng Chief Financial Officer: Dawn Carfora

DOCKE

RM

Senior Vice President, Publishing & Operations: Valerie E. Berger Vice President, Emerging Products: Debra Del Guidice Senior Vice President, Product Sales, Corporate Development & General Counsel: Andrew Gelman Senior Vice President, Sales: John Loucks Senior Vice President, Product Management: Lucian Taylor Vice President, Business Development: Tom Dieker

Director of Sales: Eileen Bruno Senior Business Manager: Karen Fass Senior Account Executive: Marjorie Jaxel Account Executives: Nick Clark, Carlos Cornejo, Michael Loechel, Hitesh Mistry, Gary Naccarato Director, Regulatory Solutions: Chris Thornton

Senior Director, Operations & Client Services: Stephanie Struble Director, Clinical Services: Sylvia Nashed, PharmD Director, Marketing: Kim Marich Client Services Manager: Kathleen O'Brien Manager, Clinical Services: Nermin Shenouda, PharmD Senior Drug Information Specialist, Database Management: Christine Sunwoo, PharmD Senior Drug Information Specialist, Product Development: Anila Patel, PharmD Drug Information Specialists: Pauline Lee, PharmD; Peter Leighton, PharmD; Kristine Mecca, PharmD Clinical Editor: Julia Tonelli, MD Managing Editor: J. Harris Fleming, Jr. Manager, Art Department: Livio Udina Senior Director, Content Operations: Jeffrey D. Schaefer

Associate Director, Content Operations, Jenney D. Schaefer Associate Director, Manufacturing & Distribution: Thomas Westburgh Senior Production Manager, PDR: Steven Maher Senior Manager, Content Operations: Noel Deloughery Senior Index Editor: Allison O'Hare Index Editor: Julie L. Cross Senior Production Coordinator: Yasmin Hernández Production Coordinators: Eric Udina, Christopher Whalen Associate Manager, Fulfillment: Gary Lew Web Operations and Customer Service Manager: Lee Reynolds

Copyright © 2011 PDR Network, LLC. Published by PDR Network, LLC at Montvale, NJ 07645-1725. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. Physicians' Desk Reference® and PDR® are registered trademarks of PDR Network, LLC. PDR® for Ophthalmic Medicines; PDR® for Nonprescription Drugs; PDR® harmacopoeia; and PDR® are trademarks of PDR Network, LLC.

ISBN: 978-1-56363-800-8

#### **REPORT SUSPECTED ADVERSE DRUG EVENTS NOW at RxEvent.org**

Table 9. Summary of Efficacy Data*				
	Study 1	Study 2		
$ \begin{array}{c} \left[ \left( \frac{1}{2} + 1 \right)^{2} + \left( \frac{1}{2} + 1 \right)^{$	Zevalin therapeutic regimen N = 54	Zevalin therapeutic regimen N = 64	Rituximab N = 66	
Overall Response Rate (%)	n farwer 1 <b>74</b> reed y	83	55	
Complete Response Rate <sup>†</sup> (%) with a structure	1 <b>5</b>	38		
Médian DR <sup>‡,§</sup> (Months): [Range <sup>§</sup> ] traditional de la constant	6.4 [0.5-49.9+]	14.3 [1.8-47.6+]	11.5 [1.2-49.7+]	
Median TTP <sup>‡</sup> ,"(Months) [Range <sup>#</sup> ]	6.8 [1.1-50.9+]	12.1 [2.1-49.0+]	10.1 [0.7-51.3+]	
Menian TTP","(Months) [Range"] * IWRC: International Workshop Respo † CRu and CR: Unconfirmed and confir	[1.1-50.9+]		[0.7-	

± Estimated with observed range

§ Duration of response: interval from the onset of response to disease progression

¶ "+" indicates an ongoing response # Time to Disease Progression; interval from the first infusion to disease progression

men (83% vs. 55%, p<0.001). Time-to-disease-progression was not significantly different between study arms. Table 9 summarizes efficacy data from Study 2. [See table 9 above]

Study 3 was a single arm study of 30 patients of whom 27 had relapsed or refractory low-grade, follicular NHL and a platelet count 100,000 to 149,000/mm<sup>2</sup>. Patients with  $\geq$  25% lymphomatous marrow involvement, prior myeloablative therapy with stem cell support, prior external beam radiation to > 25% of active marrow or neutrophil count <1,500/mm<sup>3</sup> were ineligible for Study 3. All patients received Y-90 Zevalni [0.3 mCi per kg (11.1 ME) per kg)]. Objective, durable clinical responses were observed [89% ORR (95% CI: 70-97%) with a median duration of response of 11.6 months (range: 1.0-42.4+ months)].

14.2 Folicular, B-Cell NHL Upon Completion of First-Line Chemotherapystal back solitants waterated in the strength ask.

Study 4 was a multi-center, randomized, open-label study conducted in patients with follicular NHL with a partial (PR) or complete response (GR/CRu) upon completion of first-line chemotherapy. Randomization was stratified by center and response to first-line therapy (CR or PR). Key eligibility criteria were <25% bone marrow involvement, no prior external beam radiation or myeloablative therapy, and recovery of platelets to normal levels. Patients were ran domized to receive Zevalin (n=208) or no further therapy (n=206). Y-90 Zevalin was administered at least 6 weeks but no more than 12 weeks following the last dose of chemothera apy. The main efficacy outcome measure was progressionfree survival (PFS) assessed by study investigators using the International Workshop to Standardize Response Criter at for non-Hodgkin's Lymphomia (1999).

Among the 414 patients, 49% were male, 99% were Caucasian, 12% were 265 years old, 83% had a WHO performance status of 0, and 65% had Stage IV disease. Thirty-nine (9.5%) patients received single agent chlorambucil, 22 (5%) patients received fludarabine or a fludarabine-containing regimen, 294 (71%) patients received cyclophosphamidecontaining combination chemotherapy [CHOP (31%); CHOP-like (15%); CVP/COP (26%)] and 59 (14%) patients received rituximab-containing combination chemotherapy as first-line treatment.

Progression-free survival was significantly prolonged among Zevalin-treated patients compared to those receiving no further treatment [median PFS 38 months vs. 18 months; HR 0.46 (95% CI: 0.35, 0.60) pc0.0001 Cox model stratified by response to first-line therapy and initial treatment strategy (immediate vs. watch-and-wait)]. The number of patients who died was too small to permit a reliable comparison on survival.

The results for PFS are presented in Figure 1. doi: 10.000 [See figure 1 at top of next column]  $(1.92 \pm 0.000)$  (See figure 1 at top of next column) (1.92 \pm 0.0000) (1.92 \pm 0.0000)


16 HOW SUPPLIED/STORAGE AND HANDLING There are two kits necessary for preparation of the Zevalin therapeutic regimen: one for preparation of In-111 radiolabeled Zevalin (NDC 68152-104-04) and one for preparation of Y-90 radiolabeled Zevalin (NDC 68152-103-03). The contents of all vials are sterile, pyrogen-free, contain no preservatives, and are not radioactive. Each kit contains four identification labels and the following four vials:

- 1. One (1) Zevalin vial containing 3.2 mg ibritumomab tiuxetan in 2 mL 0.9% Sodium Chloride as a clear, colorless solution.
- One (1) 50 mM Sodium Acetate Vial containing 13.6 mg Sodium Acetate trillydrate in 2 mL Water for Injection, USP as a clear, colorless solution.

RM

DOCKE

Figure 1. Study 4: Kaplan-Meler Estimator for Investigator-Assessed Progression Free Survival Time



3. One (1) Formulation Buffer Vial containing 750 mg Albumin (Human), 76 mg Sodium Chloride, 28 mg Sodium Phosphate Dibasic Dodecahydrate, 4 mg Pentetic Acid, 2 mg Potassium Phosphate Monobasic and 2 mg Potassium Chloride in 10 mL Water for Injection, pH 7.1 as a clear vellow to amber colored solution.

a clear yellow to amber colored solution. 4. One (1) empty Reaction Vial. Indium-111 Chloride Sterile Solution (In-111 Chloride) must be ordered separately from either GE Healthcare, or Mallinckrott/Covidien.

Yttrium-90 Chloride Sterile Solution is shipped directly from the supplier upon placement of an order for the Y-90 Zevalin kit.

Rituximab (Rituxan<sup>®</sup>, Biogen Idec and Genentech USA) must be ordered separately.

Storage Store kits at 2-8°C (36-46°F). Do not freeze.

17 PATIENT COUNSELING INFORMATION

Advise patients:

• To contact a healthcare professional for severe signs and symptoms of infusion reactions.

- To take premedications as prescribed [see Dosage and Administration (2.2) and Warnings and Precautions (5.1)].
- To report any signs or symptoms of cytopenias (bleeding, easy bruising, petechiae or purpura, pallor, weakness or fatime).
- To avoid medications that interfere with platelet function, except as directed by a healthcare professional [see Warnings and Precautions (5.2)].

To seek prompt medical evaluation for diffuse rash, bullae, or desquamation of the skin or oral mucosa.
To immediately report symptoms of infection (e.g. pyrexia)

To immediately report symptoms of infection (e.g. pyrexia) [see Adverse Reactions (6.3)].
That immunization with live viral vaccines is not recom-

- That immunization with live viral vaccines is not recommended for 12 months following the Zevalin therapeutic regimen [see Warnings and Precautions (5.8)].
  To use effective contraceptive methods during treatment
- To use effective contraceptive methods during treatment and for a minimum of 12 months following Zevalin therany
- To discontinue nursing during and after Zevalin treatment
- [see Use In Special Populations (8.3)]. © 2009 Spectrum Pharmaceuticals, Inc.

Irvine, CA 92618 U.S. License No. 1832

Protected by U.S. Patent Nos. 5,736,137, 5,776,456, 5 848,439 6 907 858 6 399 061 6 689 734 6 694 840

7,543,439, 6,207,358, 6,399,061, 6,682,734, 6,994,840, 7,229,620, 7,381,560, 7,422,739 and other patents and patents pending. Direct Inquiries to: Professional Services Department 1-888-STIEFEL (1-888-784-3335) DUAC<sup>®</sup>

Stiefel Laboratories, Inc. Research Triangle Park, NC 27709

(clindamycin phosphate, 1% - benzoyl peroxide, 5%) Topical Gel For Dermatological Use Only.


Not for Ophthalmic Use. Rx Only

DESCRIPTION

Duac<sup>®</sup> Topical Gel contains clindamycin phosphate, (7(S)chloro-7-deoxylincomycin-2-phosphate), equivalent to 1% clindamycin, and 5% benzoyl peroxide.

Clindamycin phosphate is a water soluble ester of the semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.

Clindamycin phosphate is  $\rm C_{18}H_{34}ClN_2O_8PS$ . The structural formula for clindamycin phosphate is represented below:



Clindamycin phosphate has a molecular weight of 504.97 and its chemical name is methyl 7-chloro-6,7,2-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1thio-L-threo-a-D-galacto-octopyranoside 2-(dihydrogen phosphate). Benzoyl peroxide is  $C_{14}H_{10}O_4$ . It has the following struc-

tural formulaite of 2014/00 of the test set of the origination of the spin set of the test of test of

(a) Alita ana alita A

Benzoyl peroxide bas a molecular weight of 242.23. Each gram of Duac<sup>6</sup> Topical Gel contains 10 mg (1%) clindamycin, as phosphate, and 50 mg (5%) benzoyl peroxide in a base consisting of carbomer homopolymer (type C), dimethicone, disodium lauryl sulfosuccinate, edetate disodium, glycerin, methylparaben, polozamer 182, purified water, silicon dioxide, and sodium hydroxide.

CLINICAL PHARMACOLOGY

A comparative study of the pharmacokinetics of Duac<sup>9</sup> Topical Gel and 1% clindamycin solution alone in 78 patients indicated that mean plasma clindamycin levels during the four week dosing period were < 0.5 ng/ml for both treatment groups.

Benzoyl peroxide has been shown to be absorbed by the skin where it is converted to benzoic acid. Less than 2% of the dose enters systemic circulation as benzoic acid. Microbiology

# Mechanism of Action

Clindamycin binds to the 50S ribosomal subunits of susceptible bacteria and prevents elongation of peptide chains by interfering with peptidyl transfer, thereby suppressing protein synthesis. Benzoyl peroxide is a potent oxidizing agent.

In Vivo Activity

No microbiology studies were conducted in the clinical trials with this product. In Vitro Activity

The clindamycin and benzoyl peroxide components individually have been shown to have *in vitro* activity against *Propionibacterium acnes*, an organism which has been associ ated with acne vulgaris; however, the clinical significance of this is not known.

Drug Resistance There are reports of an increase of *P. acnes* resistance to clindamycin in the treatment of acne. In patients with *P. acnes* resistant to clindamycin, the clindamycin component may provide no additional benefit beyond benzoyl peroxide alone.

RECEIVE FDA REQUIRED DRUG ALERTS INSTANTLY ONLINE, REGISTER at PDR.net

Ŗ.

Find authenticated court documents without watermarks at docketalarm.com.

#### Mean percent reduction in inflammatory lesion counts

	Study 1	Study 2 (n=273)	Study 3 (n=280)	Study 4 (n=288)	Study 5 (n=358)
Duac <sup>®</sup> Topical Gel	(n=120) 65%	56%	42%	57%	52%
Benzoyl Peroxide	36%	37%	32%	57%	41%
Clindamycin	34%	30%	38%	49%	33%
Vehicle	19%	-0.4%	29%		29%

Local reactions with use of Duac® Topical Gel % of patients using Duac® Topical Gel with symptom present Combined results from 5 studies (n=397)

Bef	Before	re Treatment (Baseline)		During Treatment		
an e se ge	Mild	Moderate	Severe	Mild	Moderate	Severe
Erythema	28%	3%	0	26%	5%	,
Peeling	6%	<1%	0	17%	2%	0
Burning	3%	<1%	<sup>* y **</sup> : 0 · · · ·		- <b>&lt;1%</b>	naar ( <b>0</b> - geo
Dryness	6%	<1%	0	15%	1%	0

#### CLINICAL STUDIES

In five randomized, double-blind clinical studies of 1,319 pa-tients, 397 used Duac<sup>®</sup> Topical Gel, 396 used benzoyl peroxide, 349 used clindamycin and 177 used vehicle. Duac<sup>®</sup> Topical Gel applied once daily for 11 weeks was significantly more effective than vehicle, benzoyl peroxide, and clindamycin in the treatment of inflammatory lesions of moderate to moderately severe facial acne vulgaris in three of the five studies (Studies 1, 2, and 5).

Patients were evaluated and acno lesions counted at each clinical visit: weeks 2, 5, 8, 11. The primary efficacy measures were the lesion counts and the investigator's global assessment evaluated at week 11. Patients were instructed to wash the face, wait 10 to 20 minutes, and then apply medication to the entire face, once daily, in the evening be-fore retiring. Percent reductions in inflammatory lesion counts after treatment for 11 weeks in these five studies are shown in the following table:

See first table above) The Duac<sup>®</sup> Topical Gel group showed greater overall im-provement in the investigator's global assessment than the benzoyl peroxide, clindamycin and vehicle groups in three of the five studies (Studies 1, 2, and 5).

Clinical studies have not adequately demonstrated the effectiveness of Duac<sup>3</sup> Topical Gel versus benzoyl peroxide alone in the treatment of non-inflammatory lesions of acne. INDICATIONS AND USAGE

Duac<sup>®</sup> Topical Gel is indicated for the topical treatment of

inflammatory acne vulgaris. Duac<sup>®</sup> Topical Gel has not been demonstrated to have any additional benefit when compared to benzoyl peroxide alone in the same vehicle when used for the treatment of noninflammatory acne. sa.

#### CONTRAINDICATIONS

Duac<sup>®</sup> Topical Gel is contraindicated in those individuals who have shown hypersensitivity to any of its components or to lincomycin. It is also contraindicated in those having a history of regional enteritis, ulcerative colitis, pseudomem-branous colitis, or antibiotic-associated colitis.

#### WARNINGS

DOCKET

ORALLY AND PARENTERALLY ADMINISTERED CLINDAMYCIN HAS BEEN ASSOCIATED WITH SEVERE CO-LITIS WHICH MAY RESULT IN PATIENT DEATH. USE OF THE TOPICAL FORMULATION OF CLINDAMYCIN RESULTS IN ABSORPTION OF THE ANTIBIOTIC FROM THE SKIN SUR-FACE. DIARRHEA, BLOODY DIARRHEA, AND COLITIS (IN-CLUDING PSEUDOMEMBRANOUS COLITIS) HAVE BEEN REPORTED WITH THE USE OF TOPICAL AND SYSTEMIC CLINDAMYCIN. STUDIES INDICATE A TOXIN(S) PRO-DUCED BY CLOSTRIDIA IS ONE PRIMARY CAUSE OF ANTIBIOTIC-ASSOCIATED COLITIS. THE COLITIS IS USU-ALLY CHARACTERIZED BY SEVERE PERSISTENT DIAR-RHEA AND SEVERE ABDOMINAL CRAMPS AND MAY BE ASSOCIATED WITH THE PASSAGE OF BLOOD AND MU-CUS. ENDOSCOPIC EXAMINATION MAY REVEAL PSEUDO-MEMBRANOUS COLITIS. STOOL CULTURE FOR Clostridium difficile AND STOOL ASSAY FOR Clostridium difficile TOXIN MAY BE HELPFUL DIAGNOSTICALLY. WHEN SIG-NIFICANT DIARRHEA OCCURS, THE DRUG SHOULD BE DISCONTINUED, LARGE BOWEL ENDOSCOPY SHOULD BE

CONSIDERED TO ESTABLISH A DEFINITIVE DIAGNOSIS IN CASES OF SEVERE DIARRHEA, ANTIPERISTALTIC AGENTS SUCH AS OPIATES AND DIPHENOXYLATE WITH ATROPINE MAY PROLONG AND/OR WORSEN THE CONDITION DIAR-RHEA, COLITIS AND PSEUDOMEMBRANOUS COLITIS HAVE BEEN OBSERVED TO BEGIN UP TO SEVERAL WEEKS FOLLOWING CESSATION OF ORAL AND PAREN-TERAL THERAPY WITH CLINDAMYCIN.

Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases. consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against Clostridium difficile colitis.

#### PRECAUTIONS

General

For dermatological use only; not for ophthalmic use, Con-comitant topical acne therapy should be used with caution because a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents.

The use of antibiotic agents may be associated with the overgrowth of nonsusceptible organisms, including fungi. If this occurs, discontinue use of this medication and take appropriate measures.

Avoid contact with eves and mucous membranes Clindamycin and erythromycin containing products should not be used in combination. In vitro studies have shown antagonism between these two antimicrobials. The clinical significance of this in vitro antagonism is not known.

Information for Patients Patients using Duac<sup>®</sup> Topical Gel should receive the follow-

ing information and instructions: 1. Duac<sup>®</sup> Topical Gel is to be used as directed by the physi-

- cian. It is for external use only. Avoid contact with eyes, and inside the nose, mouth, and all mucous membranes, as this product may be irritating. 2. This medication should not be used for any disorder other
- than that for which it was prescribed.
- 3. Patients should not use any other topical acne prepara-tion unless otherwise directed by their physician.
- 4. Patients should report any signs of local adverse reac-tions to their physician. Patients who develop allergic symptoms such as severe swelling or shortness of breath should discontinue use and contact their physician imme-
- diately. 5. Duac<sup>®</sup> Topical Gel may bleach hair or colored fabric. 6. Duac<sup>®</sup> Topical Gel can be stored at room temperature up 6. duac<sup>®</sup> Topical Gel can be stored at room temperature up to 25°C (77°F) for up to 2 months. Do not freeze. Keep tube tightly closed. Keep out of the reach of small chil-dren. Discard any unused product after 2 months. 7. Before applying Duac<sup>9</sup> Topical Gel to affected areas, wash the skin gently, rinse with warm water, and pat dry.
- 8. Excessive or prolonged exposure to sunlight should be limited. To minimize exposure to sunlight, a hat or other clothing should be worn.

Carcinogenesis, Mutagenesis, Impairment of Fertility Benzoyl peroxide has been shown to be a tumor promoter and progression agent in a number of animal studies. Benzoyl peroxide in acetone at doses of 5 and 10 mg administered twice per week induced squamous cell skin tumors

FREE CME AND LIABILITY REDUCTION SERVICES at PDR.net

# FIND PATIENT SUPPORT RESOURCES at PDR.net

in transgenic TgAC mice in a study using 20 weeks of topical treatment. The clinical significance of this is unknown. In a 2-year dermal cercinogenicity study in mice, treatment with Duac<sup>®</sup> Topical Gel at doses up to 8000 mg/kg/day (16 times the highest recommended adult human dose of 2.5 g Duac<sup>®</sup> Topical Gel, based on mg/m<sup>2</sup>) did not cause an in-Crease in skin tumors. However, topical treatment with an-other formulation containing 1% clindamycin and 5% benzoyl peroxide at doses of 100, 500, or 2000 mg/kg/day caused a dose-dependent increase in the incidence of keratoacanthoma at the treated skin site of male rats in a 2-year dermal carinogenicity study in rats.

In a 52-week photocarcinogenicity study in hairless mice (40 weeks of treatment followed by 12 weeks of observation), the median time to onset of skin tumor formation decreased and the number of tumors per mouse increased relative to controls following chronic concurrent topical treatment with Duac<sup>®</sup> Topical Gel and exposure to ultraviolet radiation.

Genotoxicity studies were not conducted with Duac<sup>®</sup> Topical Gel. Clindamycin phosphate was not genotoxic in Salmonella typhimurium or in a rat micronucleus test. Benzoyl peroxide has been found to cause DNA strand breaks in a variety of mammalian cell types, to be mutagenic in Salmo nella typhimurium tests by some but not all investigators. and to cause sister chromatid exchanges in Chinese ham ster ovary cells.

Studies have not been performed with Duac® Topical Gel or benzojl peroxide to evaluate the effect on fertility. Fertility studies in rats treated orally with up to 300 mg/kg/day of clindamycin (approximately 120 times the amount of clindamycin in the highest recommended adult human dose of 2.5 g Duac<sup>®</sup> Topical Gel, based on mg/m<sup>2</sup>) revealed no effects on fertility or mating ability. Pregnancy

#### Teratogenic Effects

Pregnancy Category C Animal reproduction studies have not been conducted with Duac<sup>®</sup> Topical Gel or benzoyl peroxide. It is also not known whether Duac<sup>®</sup> Topical Gel can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Duac<sup>®</sup> Topical Gel should be given to a pregnant oman only if clearly needed.

Developmental toxicity studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (240 and 120 times the amount of clindamycin in the highe estrec ommended adult human dose based on mg/m<sup>2</sup>, respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (100 and 50 times the amount of clindamycin in the highest recommended adult human dose based on mg/m2, respectively) revealed no evidence of teratogenicity. Nursing Women

It is not known whether Duac® Topical Gel is secreted into human milk after topical application. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness of this product in pediatric patients below the age of 12 have not been established

ADVERSE REACTIONS

During clinical trials, all patients were graded for facial erythema, peeling, burning, and dryness on the following scale: 0 = absent, 1 = mild, 2 = moderate, and 3 = severe. The percentage of patients that had symptoms present before treatment (at baseline) and during treatment were as follows: [See second table above]'

(Percentages derived by # subjects with symptom score/# enrolled Duac<sup>®</sup> Topical Gel subjects, n = 397).

Anaphylaxis, as well as allergic reactions leading to hospitalization, has been reported in post-marketing use with Topical Gel. Because these reactions are reported vol-Duac untarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to a drug exposure.

#### DOSAGE AND ADMINISTRATION

Duac<sup>®</sup> Topical Gel should be applied once daily, in the evening or as directed by the physician, to affected areas after the skin is gently washed, rinsed with warm water and patted dry.

#### HOW SUPPLIED

Duac<sup>®</sup> (clindamycin, 1% - benzoyl peroxide, 5%) Topical Gel is available in:

• 45 gram tube NDC 0145-2371-05

Prior to Dispensing: Store in a cold place, preferably in a refrigerator, between 2°C and 8°C (36°F and 46°F). Do not freeze

## **REPORT SUSPECTED ADVERSE DRUG EVENTS NOW at RxEvent.org**

### **EVOCLIN • STIEFEL/2767**

4 (3%)

Dispensing Instructions for the Pharmacist: Dispense Duac<sup>®</sup> Topical Gel with a 60 day expiration date and specify "Store at room temperature up to 25°C (77°F). Do not freeze Keep tube tightly closed. Keep out of the reach of small children ©2010 Stiefel Laboratories, Inc. Stiefel Laboratories, Inc. Research Triangle Park, NC 27709

DUA:3PI

Rev. February 2011 DUAC is a registered trademark of Stiefel Laboratories,

# Inc

# **EVOCLIN®**

[ĕ-vö-klĭn] (clindamycin phosphate) Foam, 1% For Topical Use

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EVOCLIN Foam safely and effectively. See full prescribing information for EVOCLIN Foam. EVOCLIN<sup>®</sup> (clindamycin phosphate) Foam, 1% For Topical Use

Initial U.S. Approval: 1970

INDICATIONS AND USAGE

EVOCLIN Foam is a lincosamide product indicated for acne vulgaris in patients 12 years and older. (1)

- DOSAGE AND ADMINISTRATION · For topical use only; not for oral, ophthalmic, or intravaginal use. (2)

• Apply EVOCLIN Foam once daily to affected areas. (2) · Flammable; avoid fire, flame and/or smoking during and immediately following application. (2)

# - DOSAGE FORMS AND STRENGTHS -

Foam containing 1% clindamycin as clindamycin phosphate. (3)

#### -CONTRAINDICATIONS

EVOCLIN Foam is contraindicated in individuals with a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis. (4)

#### - WARNINGS AND PRECAUTIONS

• Colitis: Clindamycin can cause severe colitis, which may result in death. Diarrhea, bloody diarrhea, and colitis (in cluding pseudomembranous colitis) have been reported with the use of clindamycin. EVOCLIN Foam should be discontinued if significant diarrhea occurs. (5.1)

#### ADVERSE REACTIONS

The most common adverse reactions (>1%) are headache and application site reactions including burning, pruritus, and dryness. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Stiefel Laboratories, Inc. at 1-888-784-3335 (1-888-STIEFEL) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling

Revised: 07/2011

#### FULL PRESCRIBING INFORMATION: CONTENTS\*

- INDICATIONS AND USAGE
- DOSAGE AND ADMINISTRATION
- DOSAGE FORMS AND STRENGTHS 3
- CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS
- 5.1 Colitis Irritation
  - ADVERSE REACTIONS

6

DOCKET

- **Clinical Trials Experience** 6.1
- 6.2 Postmarketing Experience DRUG INTERACTIONS 7
- Erythromycin
- 7.2 Neuromuscular Blocking Agents USE IN SPECIFIC POPULATIONS 8
  - 8.1
  - Pregnancy Nursing Mothers 8.3
  - Pediatric Use 8.4
  - 8.5 Geriatric Use DESCRIPTION
- 11 12
  - CLINICAL PHARMACOLOGY
  - 12.1Mechanism of Action
    - 12.2Pharmacodynamics
    - 12.3Pharmacokinetics
  - 12.4 Microbiology NONCLINICAL TOXICOLOGY
- 13 13,1 Carcinogenesis, Mutagenesis, Impairment of Fertility

- CLINICAL STUDIES HOW SUPPLIED/STORAGE AND HANDLING 16 16.1 How Supplied
  - 16.2 Storage and Handling PATIENT COUNSELING INFORMATION
  - 17.1 Instructions for Use 17.2
    - Skin Irritation 173 Colitis

17

Ŗ

\* Sections or subsections omitted from the full prescribing information are not listed

#### FULL PRESCRIBING INFORMATION

INDICATIONS AND USAGE

EVOCLIN Foam is indicated for topical application in the treatment of acne vulgaris in patients 12 years and older.

DOSAGE AND ADMINISTRATION 2

EVOCLIN Foam is for topical use only, and not for oral, ophthalmic, or intravaginal use.

Apply EVOCLIN Foam once daily to affected areas after the skin is washed with mild soap and allowed to fully dry. Use enough to cover the entire affected area.

The contents of EVOCLIN Foam are flammable; avoid fire, flame and/or smoking during and immediately following application

#### DOSAGE FORMS AND STRENGTHS 3

White to off-white thermolabile foam. Each gram of EVOCLIN Foam contains, as dispensed, 12 mg (1.2%) of clindamycin phosphate, equivalent to 10 mg (1%) of clindamycin.

### CONTRAINDICATIONS

EVOCLIN Foam is contraindicated in individuals with a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.

WARNINGS AND PRECAUTIONS

#### 5.1 Colitis

Systemic absorption of clindamycin has been demonstrated following topical use of this product. Diarrhea, bloody diar-rhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical clindamycin. If signif-icant diarrhea occurs, EVOCLIN Foam should be discontinued. [See Adverse Reactions (6.2).]

Severe colitis has occurred following oral or parenteral ad-ministration of clindamycin with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis may result in death.

Studies indicate a toxin(s) produced by Clostridia is one primary cause of antibiotic-associated colitis. The colitis is usu-ally characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passa of blood and mucus. Stoel cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.

### Irritation

EVOCLIN Foam can cause irritation. Avoid contact of EVOCLIN Foam with eyes. If contact oc-

curs, rinse eyes thoroughly with water. EVOCLIN Foam should be prescribed with caution in atopic

individuals.

#### 6 ADVERSE REACTIONS 6.1

**Clinical Trials Experience** 

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

A total of 439 subjects with mild to moderate acne vulgaris vere treated once daily for 12 weeks with EVOCLIN Foam. The incidence of adverse reactions occurring in  ${\geq}1\%$  of the subjects in clinical trials comparing EVOCLIN Foam, and its vehicle is presented in Table 1.

#### Table 1: Adverse Reactions Occurring in ≥1% of Subjects

Adverse Reactions	Number (%) of Subjects			
	EVOCLIN Foam N = 439	Vehicle Foam N = 154		
Headache	12 (3%)	1 (1%)		
Application site burning	27 (6%)	14 (9%)		
Application site pruritus	5 (1%)	5 (3%)		
Application site dryness	4 (1%)	5 (3%)		

**RECEIVE FDA REQUIRED DRUG ALERTS INSTANTLY ONLINE, REGISTER at PDR.net** 

Find authenticated court documents without watermarks at docketalarm.com.

reaction, not otherwise specified In a contact sensitization study, none of the 203 subjects developed evidence of allergic contact sensitization to EVOCLIN Foam.

3 (1%)

#### Postmarketing Experience 6.2

Application site

The following adverse reactions have been identified during post approval use of EVOCLIN Foam: application site pain, application site erythema, diarrhea, urticaria, abdominal pain, hypersensitivity, rash, abdominal discomfort, nausea, seborrhea, application site rash, dizziness, and pain of skin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Abdominal pain and gastrointestinal disturbances, as well as gram-negative folliculitis, have also been reported in as-sociation with the use of topical formulations of clindamycin. Orally and parenterally administered clindamycin have been associated with severe colitis, which may end fatally.

### DRUG INTERACTIONS

#### Erythromycin

EVOCLIN Foam should not be used in combination with topical or oral erythromycin-containing products due to possible antagonism to its clindamycin component. In vitro studies have shown antagonism between these two antimicrobials. The clinical significance of this in vitro antagonism is not known.

# Neuromuscular Blocking Agents

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, EVOCLIN Foam should be used with caution in patients receiving such agents.

USE IN SPECIFIC POPULATIONS Pregnancy

8.1. Pregnancy Pregnancy Category B: There are no adequate and well-controlled studies in pregnant women treated with EVOCLIN Foam. EVOCLIN Foam should be used during pregnancy only if the potential benefit clearly outweighs the otential risk to the fetus.

Reproduction studies have been performed in rats and mice using subcutaneous and oral doses of clindamycin phosphate, clindamycin hydrochloride and clindamycin pal-mitate hydrochloride. These studies revealed no evidence of field harm. The highest dose used in the rat and mouse ter-atogenicity studies was equivalent to a clindamycin phosphate dose of 432 mg/kg. For a rat, this dose is 84 fold higher, and for a mouse 42 fold higher, than the anticipated human dose of clindamycin phosphate from EVOCLIN Foam based on a mg/m<sup>2</sup> comparison. 8.3 Nursing Mothers

It is not known whether clindamycin is excreted in human milk following use of EVOCLIN Foam. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

If used during lactation and EVOCLIN Foam is applied to the chest, care should be taken to avoid accidental ingestion by the infant. Pediatric Use 84

Safety and effectiveness of EVOCLIN Foam in children under the age of 12 have not been studied. Geriatric Use

The clinical study with EVOCLIN Foam did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects.

#### DESCRIPTION

11

EVOCLIN (clindamycin phosphate) Foam contains clindamycin (1%) as clindamycin phosphate. Clindamycin phosphate is a water-soluble ester of the semi-

synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic, lincomycin.

The chemical name for clindamycin phosphate is methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-py-rrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-(dihydrogen phosphate). The structural formula for clindamycin phosphate is represented below:

[See chemical structure at top of next column]

Molecular Formula: C18H34CIN2O8PS Molecular Weight: 504.97 g/mol

EVOCLIN Foam contains clindamycin (1%) as clindamycin phosphate, at a concentration equivalent to 10 mg clindamycin per gram in a thermolabile hydroethanolic